برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Odactra (house dust mite allergen extract) Sublingual Tablets Date of Approval: March 1, 2017 Company: ALK-Abelló A/S Treatment for: House Dust Mite Allergies Odactra (house dust mite allergen extract) is a sublingual allergy immunotherapy (SLIT) tablet indicated as immunotherapy for house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis. https://t.me/ppdprogram

➡️Qtern (dapagliflozin and saxagliptin) Tablets Date of Approval: February 27, 2017 Company: AstraZeneca Treatment for: Diabetes, Type 2 Qtern (dapagliflozin and saxagliptin) is a sodium-glucose cotransporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP4) inhibitor fixed-dose combination for the treatment of adult patients with type 2 diabetes. https://t.me/ppdprogram

➡️Emflaza (deflazacort) Tablets and Oral Suspension Date of Approval: February 9, 2017 Company: PTC Therapeutics, Inc. Treatment for: Duchenne Muscular Dystrophy Emflaza (deflazacort) is a glucocorticoid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. https://t.me/ppdprogram

➡️Parsabiv (etelcalcetide) Injection Date of Approval: February 7, 2017 Company: Amgen Inc. Treatment for: Secondary Hyperparathyroidism Parsabiv (etelcalcetide) is a calcium-sensing receptor agonist indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis. https://t.me/ppdprogram

➡️ArmonAir RespiClick (fluticasone propionate) Inhalation Powder Date of Approval: January 27, 2017 Company: Teva Pharmaceutical Industries Ltd. Treatment for: Asthma, Maintenance ArmonAir RespiClick (fluticasone propionate) is an inhaled corticosteroid in a breath-activated, multi-dose dry powder inhaler formulation for the treatment of asthma. https://t.me/ppdprogram

➡️AirDuo RespiClick (fluticasone propionate and salmeterol) Inhalation Powder Date of Approval: January 27, 2017 Company: Teva Pharmaceutical Industries Ltd. Treatment for: Asthma, Maintenance AirDuo RespiClick (fluticasone propionate and salmeterol) is a corticosteroid and long-acting beta2-adrenergic agonist (LABA) combination in a breath-activated, multi-dose dry powder inhaler formulation for the treatment of asthma. https://t.me/ppdprogram

➡️Rhofade (oxymetazoline hydrochloride) Cream Date of Approval: January 18, 2017 Company: Allergan plc Treatment for: Rosacea Rhofade (oxymetazoline hydrochloride) is a topical alpha1A adrenoceptor agonist vasoconstrictor for the treatment of persistent facial erythema associated with rosacea in adults. https://t.me/ppdprogram

➡️Vaxelis (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, haemophilus b conjugate [meningococcal protein conjugate] and hepatitis B [recombinant] vaccine) Suspension for Intramuscular Injection Date of Approval: December 21, 2018 Company: Merck and Sanofi Treatment for: Diphtheria Prophylaxis, Tetanus Prophylaxis, Pertussis Prophylaxis, Poliomyelitis Prophylaxis, Hepatitis B Prevention, Haemophilus influenzae Prophylaxis Vaxelis is a hexavalent combination vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b in children from 6 weeks through 4 years of age (prior to the 5th birthday). https://t.me/ppdprogram

➡️ProAir Digihaler (albuterol sulfate) Inhalation Powder Date of Approval: December 21, 2018 Company: Teva Pharmaceutical Industries Ltd. Treatment for: Bronchospasm Prophylaxis, Asthma, COPD ProAir Digihaler (albuterol sulfate) is a beta2-adrenergic agonist indicated for the treatment or prevention of bronchospasm in patients with reversible obstructive airway disease, and the prevention of exercise-induced bronchospasm. https://t.me/ppdprogram

➡️Inbrija (levodopa) Inhalation Powder Date of Approval: December 21, 2018 Company: Acorda Therapeutics, Inc. Treatment for: Parkinson's Disease Inbrija (levodopa) is an oral inhalation formulation of the approved drug levodopa for the treatment of OFF episodes in people with Parkinson’s disease taking a carbidopa/levodopa regimen. https://t.me/ppdprogram

➡️Motegrity (prucalopride) Tablets Date of Approval: December 14, 2018 Company: Shire plc Treatment for: Chronic Idiopathic Constipation Motegrity (prucalopride) is a selective serotonin type 4 (5‑HT4) receptor agonist for the treatment of chronic idiopathic constipation (CIC) in adults. https://t.me/ppdprogram

➡️Tolsura (itraconazole) Capsules Date of Approval: December 11, 2018 Company: Mayne Pharma Treatment for: Blastomycosis; Histoplasmosis; Aspergillosis Tolsura (itraconazole) is an azole antifungal indicated for the treatment of certain fungal infections including blastomycosis, histoplasmosis and aspergillosis. https://t.me/ppdprogram

➡️Elepsia XR (levetiracetam) Extended-Release Tablets Date of Approval: December 20, 2018 Company: Sun Pharma Global Treatment for: Epilepsy Elepsia XR (levetiracetam) is an extended-release formulation of the antiepileptic drug levetiracetam designed to reduce pill burden in patients receiving high doses for the treatment of partial onset seizures. https://t.me/ppdprogram

➡️Dextenza (dexamethasone) Ophthalmic Insert Date of Approval: November 30, 2018 Company: Ocular Therapeutix, Inc. Treatment for: Postoperative Ocular Inflammation, Conjunctivitis, Allergic Dextenza (dexamethasone ophthalmic insert) is a corticosteroid intracanalicular insert for the treatment of post-surgical ocular inflammation and pain, and ocular itching associated with allergic conjunctivitis https://t.me/ppdprogram

➡️Aemcolo (rifamycin) Delayed-Release Tablets Date of Approval: November 16, 2018 Company: Cosmo Technologies, Ltd. Treatment for: Traveler's Diarrhea Aemcolo (rifamycin) is a broad spectrum, orally non-absorbable antibiotic for the treatment of traveler’s diarrhea caused by noninvasive strains of Escherichia coli. https://t.me/ppdprogram

➡️Yupelri (revefenacin) Inhalation Solution Date of Approval: November 9, 2018 Company: Theravance Biopharma, Inc. Treatment for: COPD Yupelri (revefenacin) is a long-acting muscarinic antagonist (LAMA) for the treatment of chronic obstructive pulmonary disease (COPD). https://t.me/ppdprogram

➡️Bryhali (halobetasol propionate) Lotion - formerly Jemdel Date of Approval: November 6, 2018 Company: Ortho Dermatologics Treatment for: Plaque Psoriasis Bryhali (halobetasol propionate) is a high-potency topical corticosteroid formulation for the treatment of plaque psoriasis in adults. https://t.me/ppdprogram

➡️Dsuvia (sufentanil) Sublingual Tablets Date of Approval: November 2, 2018 Company: AcelRx Pharmaceuticals, Inc. Treatment for: Pain Dsuvia (sufentanil) is a synthetic opioid analgesic formulation for the management of acute pain that is severe enough to require an opioid analgesic, and for which alternative treatments are inadequate. https://t.me/ppdprogram

➡️Bijuva (estradiol and progesterone) Capsules - formerly TX-001HR Date of Approval: October 28, 2018 Company: TherapeuticsMD, Inc. Treatment for: Menopausal Vasomotor Symptoms Bijuva (estradiol and progesterone) is a bio-identical hormone combination for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) due to menopause. https://t.me/ppdprogram

➡️Xofluza (baloxavir marboxil) Tablets and Granules for Oral Suspension Date of Approval: October 24, 2018 Company: Genentech, Inc. Treatment for: Influenza Xofluza (baloxavir marboxil) is a polymerase acidic (PA) endonuclease inhibitor for the treatment of influenza, and for the post-exposure prophylaxis of influenza in people 12 years of age and older. https://t.me/ppdprogram